secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monopar Therapeutics (MNPR)
CIK:        0001645469
Form:       8-K
Filed at:   2026-05-29T20:56:34+00:00
Accession:  0001437749-26-018896
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monopar presents Phase 2 data for ALXN1840 in Wilson disease at EASL 2026
-------------------------------------------------------------------------

- ALXN1840 (tiomolibdate choline) Phase 2 study results presented at EASL International Liver Congress 2026.
- Study evaluated effect on liver pathology and clinical symptoms in Wilson disease patients.
- No specific efficacy or safety figures provided in the 8-K text; presentation is an image exhibit.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645469/000143774926018896/0001437749-26-018896-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645469/000143774926018896/mnpr20260529_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-018896

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer